Comprehensive correction of metabolic disorders in patients with myelodysplastic syndrome
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Background. Comorbid conditions, particularly metabolic syndrome (MS), in patients with hemoblastoses deserve due attention from clinicians, because metabolic disorders are a confirmed prerequisite for chronic inflammation, which significantly affects the clinical course of myelodysplastic syndrome (MDS) and acute myeloid leukemia. The purpose of the study was to investigate the effectiveness of comprehensive correction of metabolic disorders in patients with MDS. Materials and methods. To study the effectiveness of comprehensive correction of carbohydrate and lipid metabolism indicators, participants were divided into 2 groups. Group 1 (n = 33) included patients who had previously been diagnosed with MS and prediabetes and in whom recommendations for lifestyle changes did not give the expected result; such patients were prescribed rosuvastatin at a dose of 5 mg once a day with food and metformin 500 mg once a day. Group 2 (n = 33) included patients who were first prescribed a diet in accordance with recommendations and physical activity without pharmacotherapeutic intervention. Results. The study showed that adequately planned management of MS at a certain stage is effective and has predictable results, indicating a tendency to normalize lipid and carbohydrate metabolism: low- and high-density lipoproteins, triglycerides, total cholesterol, glucose and glycated hemoglobin. This is important primarily because MS is a proven prerequisite for a chronic systemic inflammatory state, which is essentially the main factor influencing the clinical course of MDS. In the dynamics of observation, we also noted a clear trend of decreasing activity of the pro-inflammatory cytokine interleukin-6 in group 1: if before the start of treatment the average indicator was 13.3 ± 1.8 pg/ml, then after a month, it became 10.9 ± 1.6 pg/ml, and after 3 months — 5.9 ± 0.9 pg/ml. In group 2, a similar scenario was observed: the level of interleukin-6 gradually decreased from 16.0 ± 0.8 pg/ml before the start of therapeutic intervention to 11.1 ± 1.2 pg/ml at the final control point. A decrease in the marker of systemic inflammation at the end of clinical observation was more significant in group 1 in which patients received metformin and rosuvastatin (compared to the data of group 2, p < 0.05). Conclusions. Correction of metabolic disorders, both with the use of pharmacotherapy and as a result of lifestyle modification in patients with MDS, is effective, as evidenced by the results of biochemical studies. Assessment of interleukin-6 levels in group 1 showed that the proposed therapeutic scenario with the use of metformin and rosuvastatin demonstrated better effectiveness in influencing the systemic inflammatory process.
Authors: H.S. Starodub, N.V. Horiainova
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: myelodysplastic syndrome, metabolic syndrome, prediabetes, carbohydrate metabolism, lipid metabolism, rosuvastatin, metformin, interleukin-6, systemic inflammation, lifestyle modification, diet and physical activity, HbA1c, chronic inflammation, acute myeloid leukemia risk, lipid profile, triglycerides
Open Access status: diamond
OpenAlex ID: W7231040455
